Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?

Aging Cell. 2002 Oct;1(1):17-21. doi: 10.1046/j.1474-9728.2002.00001.x.

Abstract

Levels of iron are increased in the brains of Parkinson's disease (PD) patients compared to age-matched controls. This has been postulated to contribute to progression of the disease via several mechanisms including exacerbation of oxidative stress, initiation of inflammatory responses and triggering of Lewy body formation. In this minireview, we examine the putative role of iron in PD and its pharmacological chelation as a prospective therapeutic for the disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Chelation Therapy / methods
  • Chelation Therapy / trends
  • Encephalitis / drug therapy
  • Encephalitis / metabolism
  • Encephalitis / physiopathology
  • Humans
  • Iron / antagonists & inhibitors*
  • Iron / metabolism*
  • Iron Chelating Agents / pharmacology*
  • Iron Chelating Agents / therapeutic use
  • Lewy Bodies / drug effects
  • Lewy Bodies / metabolism
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neurons / pathology
  • Oxidative Stress / drug effects
  • Oxidative Stress / physiology
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism*
  • Substantia Nigra / metabolism*
  • Substantia Nigra / pathology
  • Substantia Nigra / physiopathology

Substances

  • Iron Chelating Agents
  • Iron